406 related articles for article (PubMed ID: 20524813)
1. The role of iron and chelators on infections in iron overload and non iron loaded conditions: prospects for the design of new antimicrobial therapies.
Kontoghiorghes GJ; Kolnagou A; Skiada A; Petrikkos G
Hemoglobin; 2010 Jun; 34(3):227-39. PubMed ID: 20524813
[TBL] [Abstract][Full Text] [Related]
2. Ethical issues and risk/benefit assessment of iron chelation therapy: advances with deferiprone/deferoxamine combinations and concerns about the safety, efficacy and costs of deferasirox.
Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):1-15. PubMed ID: 18274978
[TBL] [Abstract][Full Text] [Related]
3. Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.
Kontoghiorghes GJ; Efstathiou A; Kleanthous M; Michaelides Y; Kolnagou A
Hemoglobin; 2009; 33(5):386-97. PubMed ID: 19814684
[TBL] [Abstract][Full Text] [Related]
4. Treating iron overload: the state of the art.
Hershko C
Semin Hematol; 2005 Apr; 42(2 Suppl 1):S2-4. PubMed ID: 15846582
[No Abstract] [Full Text] [Related]
5. Future chelation monotherapy and combination therapy strategies in thalassemia and other conditions. comparison of deferiprone, deferoxamine, ICL670, GT56-252, L1NAll and starch deferoxamine polymers.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):329-47. PubMed ID: 16798657
[TBL] [Abstract][Full Text] [Related]
6. A new era in iron chelation therapy: the design of optimal, individually adjusted iron chelation therapies for the complete removal of iron overload in thalassemia and other chronically transfused patients.
Kontoghiorghes GJ
Hemoglobin; 2009; 33(5):332-8. PubMed ID: 19814679
[TBL] [Abstract][Full Text] [Related]
7. Iron chelation therapy for transfusional iron overload: a swift evolution.
Musallam KM; Taher AT
Hemoglobin; 2011; 35(5-6):565-73. PubMed ID: 21910602
[TBL] [Abstract][Full Text] [Related]
8. Introduction of higher doses of deferasirox: better efficacy but not effective iron removal from the heart and increased risks of serious toxicities.
Kontoghiorghes GJ
Expert Opin Drug Saf; 2010 Jul; 9(4):633-41. PubMed ID: 20553089
[TBL] [Abstract][Full Text] [Related]
9. Iron mobilization using chelation and phlebotomy.
Flaten TP; Aaseth J; Andersen O; Kontoghiorghes GJ
J Trace Elem Med Biol; 2012 Jun; 26(2-3):127-30. PubMed ID: 22565013
[TBL] [Abstract][Full Text] [Related]
10. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
Kontoghiorghes GJ; Kolnagou A
Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
[TBL] [Abstract][Full Text] [Related]
11. Advances in iron overload therapies. prospects for effective use of deferiprone (L1), deferoxamine, the new experimental chelators ICL670, GT56-252, L1NA11 and their combinations.
Kontoghiorghes GJ; Eracleous E; Economides C; Kolnagou A
Curr Med Chem; 2005; 12(23):2663-81. PubMed ID: 16305464
[TBL] [Abstract][Full Text] [Related]
12. Pathogenesis and management of iron toxicity in thalassemia.
Hershko C
Ann N Y Acad Sci; 2010 Aug; 1202():1-9. PubMed ID: 20712765
[TBL] [Abstract][Full Text] [Related]
13. Chelation protocols for the elimination and prevention of iron overload in thalassaemia.
Kolnagou A; Kontoghiorghes GJ
Front Biosci (Landmark Ed); 2018 Jan; 23(6):1082-1098. PubMed ID: 28930590
[TBL] [Abstract][Full Text] [Related]
14. Monitoring long-term efficacy of iron chelation treatment with biomagnetic liver susceptometry.
Fischer R; Piga A; Harmatz P; Nielsen P
Ann N Y Acad Sci; 2005; 1054():350-7. PubMed ID: 16339683
[TBL] [Abstract][Full Text] [Related]
15. Objectives and mechanism of iron chelation therapy.
Hershko C; Link G; Konijn AM; Cabantchik ZI
Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
[TBL] [Abstract][Full Text] [Related]
16. Long term comparative studies in thalassemia patients treated with deferoxamine or a deferoxamine/deferiprone combination. Identification of effective chelation therapy protocols.
Kolnagou A; Economides C; Eracleous E; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):41-7. PubMed ID: 18274982
[TBL] [Abstract][Full Text] [Related]
17. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
[TBL] [Abstract][Full Text] [Related]
18. Iron mobilization from transferrin and non-transferrin-bound-iron by deferiprone. Implications in the treatment of thalassemia, anemia of chronic disease, cancer and other conditions.
Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):183-200. PubMed ID: 16798643
[TBL] [Abstract][Full Text] [Related]
19. Iron overload in thalassemia and related conditions: therapeutic goals and assessment of response to chelation therapies.
Porter JB; Shah FT
Hematol Oncol Clin North Am; 2010 Dec; 24(6):1109-30. PubMed ID: 21075283
[TBL] [Abstract][Full Text] [Related]
20. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
Peng CT; Tsai CH; Wu KH
Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
